Clinical Trial

Clinical Study of Multi-targeted CAR-T Therapy in Patients With Relapsed/Refractory B-Cell Lymphoma

Withdrawn Phase 1
View on ClinicalTrials.gov →
Why the trial stopped
The primary consideration is the allocation of company resources, and we have no choice but to terminate this research.
Summary
This is a single-arm, open-label clinical study evaluating the efficacy and safety of CD20/CD19/CD22 multi-targeted chimeric antigen receptor T-cell (CAR-T) injection in patients with relapsed/refractory B-cell lymphoma.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-28.
Status change: Recruiting → Withdrawn 2026-04-29
Trial Details
NCT Number NCT07093086
Lead Sponsor Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Conditions B-cell Lymphoma
Start Date 2024-11-07
Primary Completion 2026-11-30 (estimated)
Study Completion 2027-01-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-06